Flow cytometry immunophenotyping has been suggested as an adjunctive technique in the evaluation of myeloid malignancies, especially in the myelodysplastic syndromes. Its use, however, has been limited due to complexity and cost restraints. A recent study by Mayo Clinic was completed to attempt a simpler approach to flow cytometry immunophenotyping in myeloid neoplasms.
An activated partial thromboplastin clotting time (APTT) can be abnormal in a heterogeneous group of disorders. Risks associated with a prolonged APTT include hemorrhage or thrombosis, or the prolongation can have no hemostatic consequence. An abnormal APTT should always be evaluated within the context of the patient’s clinical history.
Leica Biosystems and Mayo Clinic’s Department of Laboratory Medicine and Pathology announced today a collaboration to develop the next generation of cytogenetics imaging software.
#ASH14 Live Blog [Updating]
2014 ASH Annual Meeting: Featured Resources
Mayo Clinic Symposium at ASH: Presentations Now Available
Precision and Reliability of Platelet Function Tests on Daily Antiplatelet Agent Therapy
International Research Group Publishes Updated Criteria for Diagnosing Multiple Myeloma